Compare Cassava Sciences Inc (FLNA) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kinder Morgan Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Kinder Morgan Inc trades at $32.7 (market cap $71.64B). The key difference: Kinder Morgan Inc is far larger — about 1348.1× Cassava Sciences Inc's market cap, and Kinder Morgan Inc pays a 3.65% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | KMI | |
|---|---|---|
Market Cap | $53.14M | $71.64B |
Sector | Health | Energy |
52-Week High | $4.64 | $34.31 |
52-Week Low | $1.09 | $25.84 |
Enterprise Value | -$33.43M | $103.51B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Kinder Morgan (KMI) trades at $32.55, showing minimal daily movement with a slight 0.03% gain. The stock exhibits a bearish technical signal from moving averages, while fundamentals highlight strong profitability with an 18.92% net income margin and consistent earnings beats in recent quarters. Recent news emphasizes its stable cash flows from fee-based midstream contracts and growth driven by LNG and power demand, supported by a $10.1 billion project backlog.
KMI offers a balanced outlook with stable dividend income and growth potential from natural gas infrastructure investments, but faces risks from high debt levels and commodity price volatility. Analyst sentiment is mixed with a near-even split between Buy and Hold ratings, reflecting cautious optimism amid macroeconomic uncertainties. The stock's valuation at a P/E of 21.61 appears reasonable given its cash flow stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
